Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 23:44:11 Source:politicsViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Judge blocks Biden administration from enforcing new gun sales background check rule in Texas
Next:Colin Jost left red
You may also like
- Why US Catholics are planning pilgrimages in communities across the nation
- This is why you should be taking fashion advice from Nigel Farage, Rishi Sunak and Keir Starmer
- 9 months of war will wipe out 44 years of human development in Gaza: UN report
- This is why you should be taking fashion advice from Nigel Farage, Rishi Sunak and Keir Starmer
- Georgia Republicans choose Amy Kremer, organizer of pro
- Trump says Biden is running a 'Gestapo' administration
- Donald Trump arrives at the Miami Grand Prix days after having his $250,000
- One year on, a low
- Student fatally shot, suspect detained at Georgia's Kennesaw State University